Feizhu Powder Veterinary Grade API is released as a multi-dosage-form active pharmaceutical ingredient with model designation FP-VET-API. The powder is specified for direct incorporation into tablet matrices, injectable solutions after terminal sterilization or aseptic filtration, capsule fills, oral powders, granules, feed premixes, and liquid solutions. The release specification combines pharmacopoeial monographs for veterinary substances with residual solvent and elemental impurity limits aligned to ICH Q3C and ICH Q3D. The powder is not a finished dosage form; it is a controlled input material whose particle size, polymorph form, and endotoxin burden are adjusted to the intended route of administration. For injectable grades, bacterial endotoxins are controlled below < 0.5 EU/mg according to Ph. Eur. 2.6.14. For oral and premix grades, the powder is sieved to a broader particle size distribution to reduce dust generation while retaining blend homogeneity. The manufacturer’s certificate of analysis lists the applicable model code, batch number, and release date; these fields should be verified before formulation because distributor-specific labels do not alter the primary specification.

The product is intended for use by licensed veterinary pharmaceutical manufacturers and is not released as a compounded preparation. Each batch is tested against route-specific release criteria because a powder that passes oral granule limits may not satisfy injection-grade endotoxin or particulate requirements. Separate storage and dispensing controls are required within the manufacturing facility.

Specification Envelope and Release Criteria

The release specification is divided into universal parameters and route-specific parameters. Universal parameters include identity, assay, related substances, residual solvents, elemental impurities, and loss on drying. Route-specific parameters include particle size distribution, bulk/tap density, endotoxin, and microbial limits. Table 1 lists the representative release envelope for the injection and oral/premix grades.

Analytical method validation is conducted for each dosage form because matrix effects from feed carbohydrates or tablet binders can alter retention times. The assay method is linear from 50% to 150% of target concentration, with accuracy recovery between 98.0% and 102.0% and intermediate precision relative standard deviation below 2.0%. For premix samples, extraction recovery from ground corn and soybean carriers is verified before routine batch release. The particle size method is qualified using certified reference particles with D50 values of 10 µm, 45 µm, and 150 µm to ensure system suitability. If the sample has agglomerates, dry dispersion pressure is increased stepwise from 1.0 bar to 3.0 bar until the particle size distribution reaches a plateau.

In solid dosage manufacturing, the powder is characterized by a flow function suitable for direct compression only when a glidant such as colloidal silicon dioxide is used at 0.2–0.5% w/w. Without flow aid, the angle of repose exceeds 40°, and die fill variation on a rotary press at 60,000 tablets/h increases beyond 3.0% relative standard deviation. The material should be screened through a 600 µm sieve before dry blending to de-agglomerate particles. Wet granulation is preferred for formulations requiring drug load above 50% w/w; purified water is added to a granulating bowl at 8–12% w/w while impeller speed is maintained at 200–300 rpm for 4–6 min. Over-granulation leads to particle size growth above 1.0 mm and increases tablet hardness variability. Drying in a fluid-bed dryer with inlet air temperature 50–60°C until loss on drying returns below 2.0% is required before lubrication. For capsule filling, the powder blend requires a flow aid and moisture control below 30% RH to prevent plug formation in dosator nozzles.

Granules prepared by wet granulation should be milled through a 1.0 mm screen and blended for 10 min with a V-blender at 60% fill volume. Magnesium stearate is added as a lubricant at 0.5% w/w; higher levels above 1.0% w/w reduce tablet tensile strength and slow disintegration. Tablet compression is monitored by ejection force. Deviation above 900 N at 0.5% w/w magnesium stearate indicates over-lubrication or insufficient moisture. Dissolution testing uses USP <711> apparatus II with paddle speed 50 rpm in 900 mL media; the specific medium pH is determined by the target species and gastric or intestinal release requirement. For capsules, the powder blend should achieve tapped density below 0.80 g/mL to avoid weight variation above 3.0% on high-output dosing machines.

For direct compression, a formulation containing 30% w/w API, microcrystalline cellulose, lactose monohydrate, croscarmellose sodium at 2.0% w/w, and colloidal silicon dioxide at 0.5% w/w is a starting point. The blend is mixed for 15 min in a bin blender at 12 rpm. Compression force is adjusted between 8 kN and 18 kN on a 16-station rotary press to achieve tablet hardness 60–120 N for non-coated tablets. Friability should not exceed 0.5% after 100 rotations according to Ph. Eur. 2.9.7. Disintegration time is tested in distilled water at 37 ± 2°C and should not exceed 15 min for immediate-release tablets. These values are not universal; they assume a target tablet weight of 250 mg and a final API content of 75 mg. For higher-dose veterinary formulations, the same excipient ratios may require compression force adjustments and pre-compression on a rotary press to prevent capping.

Which Processing Limits Govern Sterile Injection and Non-Sterile Liquid Solution Preparation?

Injectable solutions require the injection-grade powder with endotoxin below < 0.5 EU/mg. Dissolution is conducted in Water for Injection at 20–25°C under nitrogen purging if oxidative degradation is observed. The resulting solution is passed through a 0.45 µm clarifying filter followed by a 0.22 µm sterilizing-grade PVDF membrane. Terminal sterilization at 121°C for 15 min is permissible only where the active moiety demonstrates no assay loss above 5.0% and no increase in specified degradants above 0.2% under the selected pH. For heat-labile formulations, aseptic filtration is required, and environmental monitoring must meet EU GMP Annex 1 Grade A conditions. Sub-visible particulate matter in the final solution should comply with USP <788>: not more than 6000 particles/container at ≥ 10 µm and not more than 600 particles/container at ≥ 25 µm for volumes up to 100 mL. Osmolality and pH adjustment are formulation-specific; published data for this specific API under terminal sterilization is limited, so thermal stability studies should be completed per VICH GL3 and ICH Q1A before batch manufacture.

Filling of injectable solutions should be performed under Grade A laminar flow with Grade B background. The filling line hold time should be validated by sterile filter integrity testing before and after use. Filter compatibility studies should include adsorption loss; a loss above 5.0% across the 0.22 µm PVDF filter indicates that a polyethersulfone or asymmetric polyamide membrane should be evaluated. The solution oxygen content should be maintained below 1.0 mg/L if the API is oxygen-sensitive; nitrogen sparging before filling is used to reduce headspace oxygen. The injection grade powder should be dissolved completely before filtration; undissolved particles can blind the filter at differential pressure above 0.5 bar and reduce yield.

For non-sterile liquid solutions, the oral grade may be used, but visible particle agglomerates must be controlled by pre-dissolution screening through a 150 µm mesh. The solution should be protected from light if photodegradation screening indicates a loss above 2.0% after 24 h exposure to 500 lux. Buffer selection should avoid amine-based systems where residual aldehyde-related impurities can form Schiff bases. If a co-solvent system is required, propylene glycol or glycerol is preferred at concentrations not exceeding 40% w/w for species-specific palatability and pharmacokinetic reasons.

For oral powders and feed premixes, the API is dispersed stepwise into a carrier such as lactose monohydrate or corn starch to achieve a geometric dilution. Mixing is performed in a ribbon blender at 60% vessel fill volume for 10–15 min after the active component has been added. Blend uniformity should be tested at 10 sampling points and should achieve relative standard deviation below 5.0% for active content. In medicated premix applications, the powder is incorporated at rates determined by species-specific pharmacokinetic and residue withdrawal data; the final premix must be labeled for the intended species and withdrawal period. The premix grade is not suitable for injection or for liquid solution manufacturing because its larger particle size and higher endotoxin specification do not meet parenteral requirements. Dust containment during weighing and transfer should include local exhaust ventilation and, where batch volumes exceed 25 kg, a contained split-valve system to minimize operator exposure.

Granule formation for feed premix may use dry granulation through a roller compactor with roll pressure 30–50 kN and screen size 1.25–2.00 mm to reduce segregation during bulk transport. The resulting granules should retain a friability below 0.8% when tested according to Ph. Eur. 2.9.28; higher friability produces dust and assay non-uniformity in final feed bags. Potency distribution in a 25 kg batch should be verified at top, middle, and bottom sampling points to rule out vertical segregation.

For granule production by dry granulation, the powder is first blended with binder such as hypromellose at 3.0% w/w and lubricated with sodium stearyl fumarate at 1.0% w/w to reduce roll sticking. The roller compactor is run at roll speed 3–5 rpm and gap 2–4 mm. Milled granules are screened to a particle size range of 180–850 µm; fines below 180 µm are recycled at a rate not exceeding 30% of the fresh feed. This prevents excessive fines that would raise the angle of repose and impair die fill. Granule moisture is maintained below 1.5%.

When a Single Powder Grade Fails Across Multiple Dosage Forms

Conventional veterinary API powders often carry a single particle size specification and are not differentiated by route of administration. Feizhu Powder Veterinary Grade API differs by controlling separate grades for injection and oral/premix use. The injection grade is micronized with D90 ≤ 45 µm, endotoxin < 0.5 EU/mg, and sub-visible particle burden appropriate for sterile filtration. The oral/premix grade uses a sieve-controlled D90 ≤ 250 µm to limit dust while still permitting dispersion in dry carriers. This dual-grade approach avoids the common failure mode observed in production-scale batches where a single fine powder creates excessive dust in feed premix blending but a coarse powder blocks liquid filling needles.

Residual solvent and elemental impurity control also differ. Technical-grade veterinary powders may release with methanol above 3000 ppm or benzene above 2 ppm; Feizhu Powder is controlled to ICH Q3C and ICH Q3D limits. Polymorphic consistency is verified by XRPD; the absence of secondary polymorph reflections reduces the risk of altered dissolution rate and content uniformity drift. The powder’s Hausner ratio range 1.20–1.38 supports direct compression after glidant addition, while many unmodified APIs with Hausner ratio above 1.45 require pre-compaction or wet granulation. Moisture uptake is controlled to a critical relative humidity above 70% at 25°C; storage and processing at RH 60% or below is recommended to avoid flow loss.

Another practical difference is found in cleaning validation. Because the injection grade is micronized, it has increased adhesion to stainless steel contact surfaces; cleaning must use a validated sequence of warm purified water and detergent at 45–55°C followed by rinse. Swab recovery studies should show not less than 70% recovery from 316L stainless steel coupons. Conventional coarse powders may show lower surface adherence but present larger particle residue in poorly accessed areas. If the same production equipment is shared with other veterinary APIs, carryover limits should be based on permitted daily exposure and species-specific no-observed-adverse-effect levels. The dual-grade design of Feizhu Powder reduces the risk of using an oral-grade powder in an injectable line because the labels and CoA release limits differ visibly between grades.

At batch release, the certificate of analysis should be compared with the pharmacopoeial monograph and the registered technical file for the finished veterinary medicinal product. Deviation in residual solvent, elemental impurity, endotoxin, or polymorphic form is a basis for rejection. The powder should be stored in double polyethylene liners inside sealed fibre drums at 15–25°C and protected from light. Storage at RH above 60% requires pre-use drying to return loss on drying below 1.0%. Contact with strong oxidizing agents should be avoided; amine-bearing excipients require compatibility screening because they can induce degradation in the presence of residual aldehyde-related impurities. Batch-to-batch variance for the micronized injection grade is monitored through D10, D50, and D90 values on a laser diffraction system with dry dispersion at 3.0 bar. Published data for this specific API’s long-term stability at all dosage strengths is limited; therefore, 6-month accelerated stability data at 40°C/75% RH should be generated before assigning a shelf life longer than 24 months. The batch record should include drying time, granulation water quantity, and compression ejection force to permit retrospective investigation of content uniformity drift.